Search results for "Administration"

showing 10 items of 5106 documents

Acute parathyroid hormone increase by oral peptones administration after roux-en-Y gastric bypass surgery in obese subjects: Role of phosphate in the…

2010

It is generally considered that changes in serum phosphate levels do not alter parathyroid hormone (PTH) secretion in the absence of concomitant changes in ionized serum calcium level in humans. An acute rise in PTH was shown after phosphate administration by intraduodenal gavage in rats. We aimed to study gastrin, phosphate, PTH, ionized calcium (iCa), and blood pH responses to oral peptones in morbidly obese patients before and after roux-en-Y gastric bypass (RYGB) surgery.These parameters were evaluated in response to an oral peptone load in 24 (18 male and 6 female) obese subjects before and 6 months after RYGB surgery. In 12 gastric bypass patients, we also evaluated PTH and phosphate …

AdultMalemedicine.medical_specialtyGastric BypassAdministration OralParathyroid hormonechemistry.chemical_elementAluminum HydroxideCalciumgastric bypass phosphate parathyroid hormone ionized calcium peptonesmedicine.disease_causePhosphatesJejunumYoung Adultchemistry.chemical_compoundInternal medicineGastrinsmedicineHumansPostoperative PeriodProspective StudiesGastrinCalcium metabolismGastrointestinal tractGastric bypass surgerybusiness.industryHydrogen-Ion ConcentrationPhosphateObesity MorbidJejunumEndocrinologymedicine.anatomical_structureIntestinal AbsorptionchemistryParathyroid HormonePeptonesCalciumFemaleSurgerybusinesshormones hormone substitutes and hormone antagonistsSurgery
researchProduct

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

2008

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineRibavirinmedicineHumansProspective StudiesRapid Virologic Responsegenotype 1Hepatologybusiness.industryRibavirinStandard treatmentInterferon-alphavirus diseasesHepatitis CMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalSurgeryTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalehepatitis Cbusiness
researchProduct

Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months

2000

Abstract Background/Aims: Retreatment of relapses of chronic hepatitis C with a standard regimen of interferon plus ribavirin for 6 months obtains a sustained response in a minority of patients with high viraemia and genotype 1b . We aimed to assess whether increasing the interferon dose and prolonging the time of combined treatment may enhance the effectiveness, and also to evaluate the tolerability, and to identify the determinants of sustained response. Methods: Fifty subjects with chronic hepatitis C who had relapsed after one or more courses of α-interferon monotherapy were randomised to receive α 2 b interferon (6 MU tiw) plus ribavirin (1000–1200 mg daily) for 6 or 12 months. ALT nor…

AdultMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentAlpha interferonHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRecurrenceInterferonInternal medicineRibavirinmedicineHumansInterferon alfaChemotherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C ChronicMiddle AgedRecombinant ProteinsAnti-Bacterial AgentsSurgeryRegimenTreatment OutcomechemistryTolerabilityRNA ViralDrug Therapy CombinationFemaleComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open st…

1992

In vitro studies on the effects of dexamethasone on human synovial cells have shown that with high concentrations of the steroid in the culture medium cellular activity was completely blocked whereas with low concentrations (10(-6)M), cellular density decreased but there was an increase in the synthesis of RNA, DNA, protein and hyaluronic acid. These data, coupled with clinical experience of using intra-articular hyaluronic acid to treat patients with osteoarthritis of the knee, prompted the investigators to carry out an open, randomized study of the use of very small doses of dexamethasone in association with hyaluronic acid in 40 osteoarthritic patients. Twenty patients received a weekly …

AdultMalemedicine.medical_specialtyKnee Jointmedicine.drug_classmedicine.medical_treatmentSodium hyaluronatePainOsteoarthritismedicine.disease_causeDexamethasoneDrug Administration ScheduleInjections Intra-ArticularWeight-bearinglaw.inventionchemistry.chemical_compoundRandomized controlled triallawOsteoarthritisHyaluronic acidmedicineHumansHyaluronic AcidDexamethasoneAgedPain MeasurementChemotherapybusiness.industryDrug SynergismGeneral MedicineMiddle Agedmedicine.diseaseSurgeryMolecular WeightchemistryAnesthesiaCorticosteroidFemalebusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

2009

&lt;i&gt;Background:&lt;/i&gt; Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH. &lt;i&gt;Methods:&lt;/i&gt; Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study. &lt;i&gt;Results:&lt;/i&gt; All patients reported …

AdultMalemedicine.medical_specialtyLong term treatmentC1 inhibitor deficiencyImmunologyBradykininGastroenterologyDrug Administration ScheduleC1-inhibitorEdemaInternal medicineHumansImmunology and AllergyMedicineProspective Studiesskin and connective tissue diseasesBradykinin Receptor AntagonistsC1 esterase inhibitor deficiencyAgedbiologyAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSurgeryHereditary angioedemaImmunologybiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinInternational Archives of Allergy and Immunology
researchProduct

A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.

2002

Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects with UFT have been demonstrated in vitro. A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors.UFT and folinic acid were applied at 300 mg/m2/day and 90 mg/day, respectively, on days 1-28, repeated on day 36. Paclitaxel was applied on days 1, 8, 15 and 22 of each cycle. The starting dose of paclitaxel was 50 mg/m…

AdultMalemedicine.medical_specialtyMaximum Tolerated DosePaclitaxelmedicine.medical_treatmentLeucovorinAdministration OralPharmacologyTegafurGastroenterologyDrug Administration Schedulechemistry.chemical_compoundFolinic acidLeukocytopeniaOral administrationInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedTegafurChemotherapyDose-Response Relationship Drugbusiness.industryHematologyMiddle AgedSurvival AnalysisTreatment OutcomeOncologyPaclitaxelchemistryFluorouracilToxicityFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction…

2005

Desired adjustment of methadone dose, perceived participation in dosage regulation, and satisfaction with methadone treatment centres were assessed in a sample of opioid-dependent patients from the Valencia Region (eastern Spain). An independent interviewer asked 278 consecutively arriving patients to answer the survey, and 165 (59.4%) completed it. Adjustment of methadone dose was assessed with a -10 to +10 visual analogue scale (VAS-MD); participation in methadone dose regulation, with specific questions; and patient satisfaction, with the Verona Service Satisfaction Scale for methadone treatment (VSSS-MT). The methadone dose (mg/d) prescribed by physicians was (mean+/-S.D.) 68.0+/-30.4. …

AdultMalemedicine.medical_specialtyMethadone maintenanceAdolescentVisual analogue scalemedia_common.quotation_subjectPersonal SatisfactionToxicologyDrug Administration ScheduleHeroinPatient satisfactionDose adjustmentInternal medicinemedicineHumansPharmacology (medical)Patient participationPsychiatrymedia_commonPharmacologybusiness.industryHeroin DependenceAddictionMiddle AgedOpioid-Related DisordersPsychiatry and Mental healthSpainFemaleHealth Services ResearchPatient ParticipationbusinessAttitude to HealthMethadonemedicine.drugMethadoneDrug and alcohol dependence
researchProduct

Stratified Care vs Step Care Strategies for Migraine

2000

ContextVarious guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.ObjectiveTo compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.Design and SettingRandomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical cen…

AdultMalemedicine.medical_specialtyMetoclopramideMigraine DisordersPopulationZolmitriptanSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessHumansMedicineeducationOxazolidinonesAspirineducation.field_of_studyAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialMigraineCritical PathwaysPhysical therapyDopamine AntagonistsFemalebusinessmedicine.drugJAMA
researchProduct